Filing Overview
Registrant: 8i Acquisition 2 Corp. (proposed business combination partner of EUDA Health Holdings Ltd.)
Filing date and event date: July 7, 2022. The Form 8-K reports Regulation FD disclosure regarding an updated investor presentation and executive summary related to the proposed acquisition of EUDA Health Limited.
Transaction and Business Context
Under a Share Purchase Agreement dated April 11, 2022, as amended on May 30 and June 10, 2022, 8i Acquisition 2 Corp. agreed to purchase all issued and outstanding shares of EUDA Health Limited from Watermark Developments Limited. The transaction is intended to combine 8i Acquisition 2 Corp. with EUDA Health.
The filing furnishes an updated July 2022 investor presentation and executive summary as Exhibits 99.1 and 99.2. These materials relate to the proposed transaction and associated shareholder solicitation.
Financial Metrics and Liquidity
The filing text does not provide clear revenue, profit, cash flow, margin, debt, liquidity, valuation, or balance-sheet figures. It does state that EUDA Health has a limited operating history and a history of net losses.
The transaction remains subject to minimum cash requirements under the Share Purchase Agreement, including the effects of shareholder redemptions. No minimum cash amount or current cash balance is provided in the filing text.
Material Changes and Status
- The company furnished updated investor materials in connection with the proposed Share Purchase.
- The transaction had not been completed as of the July 7, 2022 filing date.
- 8i Acquisition 2 Corp. had filed a preliminary proxy statement, with a definitive proxy statement and other related SEC filings expected to provide additional transaction information.
Outlook, Risks, and Contingencies
Management materials include forecasts and projections regarding performance metrics and market opportunity. The filing cautions that these are forward-looking statements based on assumptions and are not guarantees of actual results.
- Completion depends on shareholder approval, satisfaction of transaction conditions, required regulatory approvals, and minimum cash requirements after redemptions.
- The transaction may not close by the stated deadline, and an extension may not be obtained.
- There is risk that the parties will not realize the anticipated benefits or maintain Nasdaq listing.
- EUDA Health faces risks associated with limited operating history, historical net losses, growth management, execution of its business plan, market acceptance, acquisitions, intellectual property, litigation, and general economic conditions.
- Costs of the business combination and potential legal proceedings may adversely affect the parties or the proposed transaction.
Investor Verification Items
- Review the definitive proxy statement and subsequent SEC filings for transaction terms, shareholder approval requirements, redemption levels, and closing conditions.
- Verify EUDA Health’s historical and projected revenue, profitability, cash flow, cash balance, debt, and minimum cash requirements.
- Assess whether required regulatory approvals and Nasdaq listing conditions were satisfied.
- Review the updated investor presentation for the basis, assumptions, and sensitivity of market-size and performance projections.
- Confirm the transaction deadline, any extension arrangements, and whether the Share Purchase was ultimately completed.